Through the Innovation Accelerator, the Cancer Service Line (CSL) and the Penn Center for Cancer Care Innovation (PC3I) at the Abramson Cancer Center (ACC) invite applications for initiatives that aim to create and test innovative solutions to address challenges in productivity, efficiency, clinician wellbeing, or access in cancer care at Penn Medicine. Proposals that seek to innovate beyond the ambulatory and hospital settings into the virtual, community, or home settings are encouraged to apply.
We seek proposals for initiatives which:
- Utilize rapid-cycle and innovation approaches to learn and iterate quickly;
- Will be executed within six months;
- Have the potential to: 1) result in large-scale improvements in cancer care, and 2) scale enterprise-wide, including across Penn Medicine entities and/or across cancer disease teams;
- Directly incorporate feedback from key stakeholders, including patients;
- Apply a health equity lens and include approaches to improve equitable access; and
- Align with Cancer Service Line priorities by proposing to improve any one or several of the following domains: productivity, efficiency, clinician wellbeing, access, and/or cancer care beyond the ambulatory and hospital settings.
Selected initiatives will be announced in early January 2023 and launch by the end of January 2023. The initiative period will be six months.
Faculty and staff from across Penn Medicine are encouraged to apply. Submissions not selected to participate in the CSL-PC3I Access Accelerator will still have access to support and advising from Penn Medicine leaders in cancer care delivery and innovation as appropriate.
- November 1, 2022: RFP Release Date
- November 10, 2022 @ 3:30-4:30pm: RFP Virtual Information Session
- November 30, 2022 @ 11:59pm: Submission Deadline
- December 6, 2022: Finalists Announced
- December 14, 2022 @ 9:00am-3:00pm: Innovation Bootcamp and Pitch for Finalists
- January 2023: Selected Initiatives Announced
- January 2023: Initiative Launch
All submissions must be received by 11:59pm ET on November 30, 2022.
Please direct any questions to Sharon Tejada at PC3I: firstname.lastname@example.org.
PC3I Faculty Roger Kim, MD, MSCE has been awarded a K08 Mentored Clinical Scientist Career Development Award from the National Cancer Institute, which provides support and mentorship to clinician scientists for research and career development activities.
PC3I is pleased to share our 2022-2023 Impact Report, which shares highlights from our work over the past year to create, test, and scale solutions to some of the most intractable problems in cancer care delivery.
A study led by PC3I Faculty Meredith Doherty, PhD, LCSW showed that patients with cancer and survivors of cancer who engaged in administrative payment tasks were more likely to experience treatment delays or treatment nonadherence.